Literature DB >> 21348515

Synthesis and pharmacological evaluation of fluorine-containing D₃ dopamine receptor ligands.

Zhude Tu1, Shihong Li, Jinquan Cui, Jinbin Xu, Michelle Taylor, David Ho, Robert R Luedtke, Robert H Mach.   

Abstract

A series of fluorine-containing N-(2-methoxyphenyl)piperazine and N-(2-fluoroethoxy)piperazine analogues were synthesized, and their affinities for human dopamine D(2), D(3), and D(4) receptors were determined. Radioligand binding studies identified five compounds, 18a, 20a, 20c, 20e, and 21e, which bind with high affinity at D(3) (K(i) = 0.17-5 nM) and moderate to high selectivity for D(3) vs D(2) receptors (ranging from ∼25- to 163-fold). These compounds were also evaluated for intrinsic activity at D(2) and D(3) receptors using a forskolin-dependent adenylyl cyclase assay. This panel of compounds exhibits varying receptor subtype binding selectivity and intrinsic activity at D(2) vs D(3) receptors. These compounds may be useful for behavioral pharmacology studies on the role of D(2)-like dopamine receptors in neuropsychiatric and neurological disorders. Furthermore, compound 20e, which has the highest binding affinity and selectivity for the D(3) receptor (K(i) = 0.17 nM for D(3), 163-fold selectivity for D(3) vs D(2) receptors), represents a candidate fluorine-18 radiotracer for in vivo PET imaging studies on the regulation of D(3) receptor expression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21348515      PMCID: PMC3066655          DOI: 10.1021/jm101323b

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  36 in total

Review 1.  Progress in developing D3 dopamine receptor ligands as potential therapeutic agents for neurological and neuropsychiatric disorders.

Authors:  Robert R Luedtkea; Robert H Mach
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

2.  Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists.

Authors:  Laura Bettinetti; Karin Schlotter; Harald Hübner; Peter Gmeiner
Journal:  J Med Chem       Date:  2002-10-10       Impact factor: 7.446

Review 3.  [Central dopamine receptors: general considerations (Part 1)].

Authors:  R Bordet
Journal:  Rev Neurol (Paris)       Date:  2004-09       Impact factor: 2.607

4.  Design, synthesis, and binding affinities of potential positron emission tomography (PET) ligands for visualization of brain dopamine D3 receptors.

Authors:  Marcello Leopoldo; Enza Lacivita; Paola De Giorgio; Nicola A Colabufo; Mauro Niso; Francesco Berardi; Roberto Perrone
Journal:  J Med Chem       Date:  2006-01-12       Impact factor: 7.446

5.  A radioisotopic method for measuring the formation of adenosine 3',5'-cyclic monophosphate in incubated slices of brain.

Authors:  H Shimizu; J W Daly; C R Creveling
Journal:  J Neurochem       Date:  1969-12       Impact factor: 5.372

6.  The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.

Authors:  Flora Mela; Mark J Millan; Mauricette Brocco; Michele Morari
Journal:  Neuropharmacology       Date:  2009-09-04       Impact factor: 5.250

7.  Autoradiographic localisation of D3-dopamine receptors in the human brain using the selective D3-dopamine receptor agonist (+)-[3H]PD 128907.

Authors:  H Hall; C Halldin; D Dijkstra; H Wikström; L D Wise; T A Pugsley; P Sokoloff; S Pauli; L Farde; G Sedvall
Journal:  Psychopharmacology (Berl)       Date:  1996-12       Impact factor: 4.530

8.  Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A.

Authors:  C Reavill; S G Taylor; M D Wood; T Ashmeade; N E Austin; K Y Avenell; I Boyfield; C L Branch; J Cilia; M C Coldwell; M S Hadley; A J Hunter; P Jeffrey; F Jewitt; C N Johnson; D N Jones; A D Medhurst; D N Middlemiss; D J Nash; G J Riley; C Routledge; G Stemp; K M Thewlis; B Trail; A K Vong; J J Hagan
Journal:  J Pharmacol Exp Ther       Date:  2000-09       Impact factor: 4.030

9.  Dyskinesia in Parkinson disease: back for the future?

Authors:  Francois J G Vingerhoets
Journal:  Neurology       Date:  2009-04-07       Impact factor: 9.910

10.  18F-Labeled FAUC 346 and BP 897 derivatives as subtype-selective potential PET radioligands for the dopamine D3 receptor.

Authors:  Carsten Hocke; Olaf Prante; Ismael Salama; Harald Hübner; Stefan Löber; Torsten Kuwert; Peter Gmeiner
Journal:  ChemMedChem       Date:  2008-05       Impact factor: 3.466

View more
  18 in total

1.  Reduction of cocaine self-administration and D3 receptor-mediated behavior by two novel dopamine D3 receptor-selective partial agonists, OS-3-106 and WW-III-55.

Authors:  Timothy H C Cheung; Amy L Loriaux; Suzanne M Weber; Kayla N Chandler; Jeffrey D Lenz; Romina F Schaan; Robert H Mach; Robert R Luedtke; Janet L Neisewander
Journal:  J Pharmacol Exp Ther       Date:  2013-09-09       Impact factor: 4.030

2.  Effect of cyclosporin A on the uptake of D3-selective PET radiotracers in rat brain.

Authors:  Zhude Tu; Shihong Li; Jinbin Xu; Wenhua Chu; Lynne A Jones; Robert R Luedtke; Robert H Mach
Journal:  Nucl Med Biol       Date:  2011-03-03       Impact factor: 2.408

3.  Pd-Catalyzed Synthesis of Piperazine Scaffolds Under Aerobic and Solvent-Free Conditions.

Authors:  Sean W Reilly; Robert H Mach
Journal:  Org Lett       Date:  2016-10-13       Impact factor: 6.005

4.  Synthesis and in vitro biological evaluation of carbonyl group-containing analogues for σ1 receptors.

Authors:  Wei Wang; Jinquan Cui; Xiaoxia Lu; Prashanth K Padakanti; Jinbin Xu; Stanley M Parsons; Robert R Luedtke; Nigam P Rath; Zhude Tu
Journal:  J Med Chem       Date:  2011-07-20       Impact factor: 7.446

5.  Absorbed radiation dosimetry of the D3-specific PET radioligand [18F]FluorTriopride estimated using rodent and nonhuman primate.

Authors:  Richard Laforest; Morvarid Karimi; Stephen M Moerlein; Jinbin Xu; Hubert P Flores; Christopher Bognar; Aixiao Li; Robert H Mach; Joel S Perlmutter; Zhude Tu
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-11-30

6.  Characterization of [(3) H]LS-3-134, a novel arylamide phenylpiperazine D3 dopamine receptor selective radioligand.

Authors:  Claudia Rangel-Barajas; Maninder Malik; Michelle Taylor; Kim A Neve; Robert H Mach; Robert R Luedtke
Journal:  J Neurochem       Date:  2014-08-19       Impact factor: 5.372

Review 7.  Selectivity of probes for PET imaging of dopamine D3 receptors.

Authors:  Robert K Doot; Jacob G Dubroff; Kyle J Labban; Robert H Mach
Journal:  Neurosci Lett       Date:  2018-03-05       Impact factor: 3.046

8.  Synthesis and pre-clinical evaluation of a potential radiotracer for PET imaging of the dopamine D3 receptor.

Authors:  Megan N Stewart; Xia Shao; Timothy J Desmond; Taylor J Forrest; Janna Arteaga; Jenelle Stauff; Peter J H Scott
Journal:  Medchemcomm       Date:  2018-06-29       Impact factor: 3.597

9.  Synthesis and in vitro pharmacological evaluation of indolyl carboxylic amide analogues as D3 dopamine receptor selective ligands.

Authors:  Zhude Tu; Shihong Li; Aixiao Li; Michelle Taylor; David Ho; Maninder Malik; Robert R Luedtke; Robert H Mach
Journal:  Medchemcomm       Date:  2013-09       Impact factor: 3.597

10.  Fos expression in response to dopamine D3-preferring phenylpiperazine drugs given with and without cocaine.

Authors:  Brian C Nolan; Shinban Liu; Lindsey R Hammerslag; Timothy H C Cheung; Jeffrey Lenz; Robert H Mach; Robert R Luedtke; Janet L Neisewander
Journal:  Synapse       Date:  2013-07-17       Impact factor: 2.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.